Neoadjuvant TKI therapy in non-metastatic GIST patients can reduce surgical complexity, with CE-CT imaging predicting benefits in 22 of 39 patients. Significant tumor volume reduction was observed ...

About 1 in every 526 people in the U.S. will be diagnosed with chronic myeloid leukemia (CML) this year, but most of these people will achieve their normal life expectancy thanks to tyrosine kinase ...

Tyrosine kinase inhibitors (TKI) are employed to attack specific types of cancer cells. The downside to using TKs is that they can cause serious inflammation. A team of researchers has discovered the ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that pivotal ...

Please provide your email address to receive an email when new articles are posted on . Platinum-doublet chemotherapy after initial response to EGFR TKI appeared associated with longer PFS but no OS ...

Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to ...

Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION. This is an ASCO Meeting Abstract from the 2017 ASCO ...

Preoperative VEGFR-TKI plus ICI therapy in advanced ccRCC normalizes tumor vasculature, enhances CD8⁺ T/B cell infiltration, and promotes TLS maturation, leading to profound tumor microenvironment ...

Treatment with a vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFR–TKI) after previous treatment with checkpoint-inhibitor therapy alone or in combination with a VEGFR–TKI ...